According to the government, investments totaling Rs 4,763.34 crore have been committed in the three and a half years under the Promotion of Bulk Drug Parks initiative till September 2025, compared to an investment commitment of Rs 4,329.95 crore over the course of six years in greenfield projects.
The PLI plan for Bulk pharmaceuticals is aimed at minimizing disruption in supply of vital Active Pharmaceutical Ingredients (APIs) needed to create crucial pharmaceuticals for which there are no substitutes by lowering supply disruption risk owing to excessive dependence on one supplier. The plan has a budgetary outlay of Rs 6,940 crore.
Additionally, 26 KSMs, DIs, and APIs that were previously mostly imported now have production capacities. The plan has resulted in cumulative sales of Rs 2,315.44 crore recorded till September 2025, including exports of Rs 508.12 crore, hence avoiding imports worth Rs 1,807.32 crore,” informed Union Minister of State for Chemicals and Fertilizers, Anupriya Patel, in a written reply in Rajya Sabha.
The PLI Scheme for Pharmaceuticals is aimed at enhancing India’s manufacturing capabilities by increasing investment and production in the pharmaceuticals sector and contributing to product diversification to high-value goods in the pharmaceutical sector and incentivises production of high-value medicines such as biopharmaceuticals, complex generic drugs, patented drugs or drugs nearing patent expiry, auto-immune drugs, anti-cancer drugs, etc. as well as production of APIs/DIs/KSMs other than those notified under the PLI Scheme for Bulk Drugs.
Its budgetary expenditure is Rs 15,000 crore. As of September 2025, the cumulative investment of Rs 40,890 crore made in the three and a half years of the program production phase in both brownfield and greenfield projects has significantly exceeded the committed investment of Rs 17,275 crore projected for the six-year lifespan of the scheme.
Further, 726 APIs/KSMs/DIs are being created under the initiative, including 191 which have been manufactured for the first time under the scheme.
Up till September 2025, the total local sales of APIs, KSMs, and DIs produced under the plan were Rs 26,123 crore, which helped prevent imports. The term of the project runs till the financial year 2028-29, according to the minister.
Read More
Leading Indian jewellery business opens its largest US store in Virginia
Revenues of India’s top three defence businesses climbed by 8.2 per cent: Report